Boehringer Ingelheim’s survodutide phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing ...
News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to ...
AI company unlocking causal human biology, today presented new preclinical data from its metabolic dysfunction-associated steatohepatitis (MASH) therapeutic development program during a podium ...
Boehringer’s Phase III data show survodutide cuts visceral & liver fat and drives weight loss, boosting its obesity/MASLD ...
In a pre‑specified sub study, survodutide achieved a reduction of up to 34% in visceral fat, while lean mass accounted for no ...
Northwestern Medicine scientists led by Joseph Bass, MD, Ph.D., the Charles F. Kettering Professor of Endocrinology and Metabolism and director of the Center for Diabetes and Metabolism, have ...
Consuming a high-fat diet can lead to a variety of health problems—not only weight gain but also an increased risk of diabetes and other chronic diseases. At the cellular level, hundreds of changes ...
Company announcement No. 21 / 2026Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and ...
CINCINNATI—Cardiac researchers at the University of Cincinnati (UC) have found a new cellular pathway that could help in developing therapeutic treatments for obesity-related disorders, like diabetes ...
The pancreas plays a critical role in both digestion and blood sugar regulation, yet many everyday habits may quietly put ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results